title: Feasibility study of zoledronic acid plus cisplatin-docetaxel as first-line treatment for advanced non-small cell lung cancer with bone metastases.
abstract: BACKGROUND
  This study evaluated the safety and efficacy of combined zoledronic acid, cisplatin and docetaxel in patients with non-small cell lung cancer (NSCLC) with bone metastases.
  
  
  METHODS
  Cisplatin 80 mg/m(2) and docetaxel 60 mg/m(2) with zoledronic acid 4 mg were given intravenously on day 1 every 3-4 weeks. The primary endpoint was feasibility of concomitant administration of zoledronic acid and cisplatin.
  
  
  RESULTS
  Thirty-five chemonaïve patients were enrolled. The median number of treatment cycles was four, and two or more cycles were administered in 29 (83%) patients without severe toxicity. No grade 3 or 4 renal toxicity was observed. The objective response rate was 29% and the 1-year survival rate was 37%. The pain score improved in 77% of the patients after six weeks.
  
  
  CONCLUSIONS
  The combination of zoledronic acid, cisplatin and docetaxel is well-tolerated with acceptable renal toxicity, and has modest activity as a first-line treatment of NSCLC patients with bone metastases.
authors.affiliation: Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan. kyoh@east.ncc.go.jp
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Yoh
authors.forename: Kaoru
authors.initials: K
authors.lastname: Kubota
authors.forename: Hironobu
authors.initials: H
authors.lastname: Ohmatsu
authors.forename: Koichi
authors.initials: K
authors.lastname: Goto
authors.forename: Seiji
authors.initials: S
authors.lastname: Niho
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Ohe
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects; D000077143:Docetaxel; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D000077211:Zoledronic Acid
chemical_list: D004164:Diphosphonates; D007093:Imidazoles; D043823:Taxoids; D000077143:Docetaxel; D000077211:Zoledronic Acid; D002945:Cisplatin